SOAT2: Sterol O-acyltransferase 2
Catalyzes the formation of fatty acid-cholesterol esters, which are less soluble in membranes than cholesterol.
- Drugs that act on it: 1
- Approved: 0
- In phases 1 to 3: 1
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on SOAT2, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 1
| Drug | Furthest stage | Sponsor | Modality | Action | Open trials |
|---|---|---|---|---|---|
| Pactimibe | Phase 2 | Daiichi Sankyo | Small molecule | InhibitorAcyl coenzyme A:cholesterol acyltransferase 2 inhibitor | 0 |
- Arteriosclerosis0.18
- Neoplasm0.09
- Hepatocellular carcinoma0.09
- Atherosclerosis0.09
- Hyperlipoproteinemia type 10.08
- Coronary atherosclerosis0.07
- Laryngeal squamous cell carcinoma0.07
- Glycogen storage disease VI0.07
- Gallbladder disease 10.06
- Congenital bile acid synthesis defect 10.06
- Familial chylomicronemia syndrome0.06
- Congenital diarrhea 7 with exudative enteropathy0.06
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4465, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-19. Gene name, function (UniProt O75908, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets